Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).

The thioether phospholipid ilmofosine (BM 41 440) is a new anti-cancer drug presently undergoing phase II clinical trials. Because resistance to anti-tumour drugs is a major problem in cancer treatment, we investigated the resistance of different cell lines to this compound. Here we report that the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, J., Utz, I., Spitaler, M., Hofer, S., Rybczynska, M., Beck, W. T., Herrmann, D. B., Grunicke, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228059/
https://www.ncbi.nlm.nih.gov/pubmed/9328144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228059/
https://www.ncbi.nlm.nih.gov/pubmed/9328144

Ejemplares similares